Analysis of daily gene activation in a patient with severe Ebola virus disease cared for at the National Institutes of Health (NIH) in 2015 found changes in antiviral and immune response genes that pinpointed key transition points in the response to infection. The changes included a marked decline in antiviral responses that correlated with clearance of virus from white blood cells. The analysis also showed that the preponderance of host responses shifted rapidly from activation of genes involved in cell damage and inflammation toward those linked to promotion of cellular and organ repair. This pivot came before the first signs of clinical improvement in the patient, who was admitted to the NIH Clinical Center on day 7 of illness and remained for 26 days. Researchers from the NIH's National Institute of Allergy and Infectious Diseases (NIAID) led the study.
The patient received intensive supportive care, including fluids and electrolytes, but did not receive any experimental Ebola drugs. The research team used blood samples taken daily throughout the patient's hospitalization and recovery to measure the rise and decline of virus replication inside white blood cells and serum and to track the timing, intensity and duration of expression of numerous immune system genes. This allowed the team to correlate changes in gene expression with subsequent alterations in the patient's clinical condition. For example, the study characterized changes associated with the development and resolution of blood clotting dysfunction and multiple organ failure during the critical phase of illness.
Although this study represents only a single case, it provides unprecedented detail on the host response to Ebola virus disease and may inform the development of therapeutics designed to boost or accelerate host factors that most effectively counter the virus and promote healing. It may also lead to better prognostic criteria to enable clinicians to tailor the treatment of patients with Ebola virus disease in ways that can best promote recovery.
In addition to NIAID, study collaborators included researchers from the NIH Clinical Center, the Institute for Systems Biology, Seattle, and the United States Army Research Institute of Infectious Diseases, Frederick, Maryland.
JC Kash et al. Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease. Science Translational Medicine DOI: 10.1126/scitranslmed.aai9321 (2017).
WHO: NIAID Director Anthony S. Fauci, M.D., is available to provide comment.
Jeffery K. Taubenberger, M.D., Ph.D., and John C. Kash, Ph.D., of the Laboratory of Infectious Diseases, NIAID, are also available to comment on their research.
To schedule interviews, please contact Anne A. Oplinger, (301) 402-1663, firstname.lastname@example.org.
NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.
NIH...Turning Discovery Into Health®